These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 106013)

  • 1. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
    Lieberman MM; McKissock DC; Wright GL
    Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
    Sensakovic JW; Bartell PF
    Infect Immun; 1977 Nov; 18(2):304-9. PubMed ID: 411754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.
    Lieberman MM
    Infect Immun; 1978 Jul; 21(1):76-86. PubMed ID: 101464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive protection by human serum in mice infected with encapsulated Staphylococcus aureus.
    Yoshida K; Ichiman Y; Narikawa S; Takahashi M; Kono E; San Clemente CL
    J Med Microbiol; 1979 Aug; 12(3):277-82. PubMed ID: 469929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.
    Gonggrijp R; Mullers WJ; van Boven CP
    Infect Immun; 1981 Jul; 33(1):178-85. PubMed ID: 6167518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonic activity of antisera to ribosomal vaccine fractions with live and formalinized Pseudomonas aeruginosa.
    Lieberman MM; Allen RC
    Can J Microbiol; 1986 Jun; 32(6):531-3. PubMed ID: 3089571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation and identification of Streptococcus dysgalactiae protective antibody in sera of rabbits and cattle.
    Stark DM; Norcross NL; Leahey JE
    J Bacteriol; 1969 Aug; 99(2):527-30. PubMed ID: 4980066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological response to a strain of Staphylococcus epidermidis in the rabbit: production of protective antibody.
    Yoshida K; Ichiman Y
    J Med Microbiol; 1978 Nov; 11(4):371-7. PubMed ID: 722780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
    Jones RJ; Hall M; Ricketts CR
    Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
    Lieberman MM; Ayala E
    J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
    [No Abstract]   [Full Text] [Related]  

  • 15. Pseudomonas aeruginosa antibodies in human plasma.
    Doi T; Yoshioka M; Nakajima T
    Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae.
    Hirao Y; Homma JY
    Infect Immun; 1978 Feb; 19(2):373-7. PubMed ID: 75846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic properties of slime produced by Pseudomonas aeruginosa.
    Maresz-Babczyszyn J; Sokalska M
    Arch Immunol Ther Exp (Warsz); 1979; 27(4):585-9. PubMed ID: 117786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
    Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
    Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.